Filing Details

Accession Number:
0001179110-12-007274
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-04-27 16:15:50
Reporting Period:
2012-04-25
Filing Date:
2012-04-27
Accepted Time:
2012-04-27 16:15:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1113481 Medicines Co MDCO Pharmaceutical Preparations (2834) 043324394
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1394777 Hiroaki Shigeta 8 Sylvan Way
Parsippany NJ 07054
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-04-25 7,500 $7.51 28,414 No 4 M Direct
Common Stock Acquisiton 2012-04-25 12,500 $8.28 40,914 No 4 M Direct
Common Stock Disposition 2012-04-25 27,500 $21.50 13,414 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option (right to buy) Disposition 2012-04-25 7,500 $0.00 7,500 $7.51
Common Stock Option (right to buy) Disposition 2012-04-25 12,500 $0.00 12,500 $8.28
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-05-28 No 4 M Direct
0 2020-06-02 No 4 M Direct
Footnotes
  1. The common stock sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 program adopted by Mr. Shigeta on March 15, 2012.
  2. As of 4/25/2012, the original grant (7,500 shares granted on 5/28/2009) was fully vested. After the exercise of the options reported hereby, as of 4/25/2012, all of the shares covered by the option were exercised.
  3. As of 4/25/2012, the original grant (12,500 shares granted on 6/2/2010) was fully vested. After the exercise of the options reported hereby, as of 4/25/2012, all of the shares covered by the option were exercised.
  4. The range of prices for the transactions reported on this line is between $21.50 and $21.54 per share. The price reported above reflects the weighted average sales price. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full informaton regarding the number of shares sold at each separate price.